Entrada Therapeutics, Inc. (TRDA)
NASDAQ: TRDA · Real-Time Price · USD
8.35
+0.23 (2.83%)
At close: Jun 6, 2025, 4:00 PM
8.32
-0.03 (-0.36%)
After-hours: Jun 6, 2025, 4:04 PM EDT
Entrada Therapeutics Employees
Entrada Therapeutics had 183 employees as of December 31, 2024. The number of employees increased by 24 or 15.09% compared to the previous year.
Employees
183
Change (1Y)
24
Growth (1Y)
15.09%
Revenue / Employee
$941,093
Profits / Employee
$135,415
Market Cap
293.34M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 183 | 24 | 15.09% |
| Dec 31, 2023 | 159 | 29 | 22.31% |
| Dec 31, 2022 | 130 | 16 | 14.04% |
| Dec 31, 2021 | 114 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 94,300 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
| AbbVie | 55,000 |
TRDA News
- 5 days ago - Entrada Therapeutics Appoints Maha Radhakrishnan, M.D., to its Board of Directors - GlobeNewsWire
- 6 days ago - Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 11 days ago - Entrada Therapeutics Receives Authorization in the European Union to Initiate ELEVATE-45-201, a Phase 1/2 Multiple Ascending Dose Clinical Study of ENTR-601-45 in Patients Living with Duchenne Muscular Dystrophy Amenable to Exon 45 Skipping - GlobeNewsWire
- 4 weeks ago - Entrada Therapeutics Reports First Quarter 2025 Financial Results - GlobeNewsWire
- 2 months ago - Entrada Therapeutics Receives Authorization in the United Kingdom to Initiate ELEVATE-45-201, a Phase 1/2 Multiple Ascending Dose Clinical Study of ENTR-601-45 in People Living with Duchenne Muscular Dystrophy Amenable to Exon 45 Skipping - GlobeNewsWire
- 3 months ago - Entrada Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results - GlobeNewsWire
- 3 months ago - Entrada Therapeutics Announces FDA Removal of Clinical Hold on ENTR-601-44 - GlobeNewsWire
- 3 months ago - Entrada Therapeutics: Cash-Rich Innovator With Asymmetric Upside - Seeking Alpha